JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Tumors of the mesentery. Apropos of 102 cases].

One hundred and two mesenteric tumours or masses are reported, and their histologic, clinical and therapeutic aspects are described: 28 cystic tumours, 38 mesenchymatous and 3 neurogenic tumours, 27 miscellaneous tumours, including 17 lymphomas, 2 hematomas and lymphoid or inflammatory masses. Seventy-four patients presented with an abdominal mass, 41 with pain and 28 with acute abdominal syndrome, including 16 with intestinal obstruction. Ultrasonography and computerised tomography were performed in 31 patients, RMI in 8 patients: these investigations are useful in establishing the diagnosis but surgical exploration and biopsies remain necessary for the pathology. One hundred and one patients required operation: 45 biopsies with 5 by-passes, and 56 resections, 32 localized tumour resections and 24 extended to the small bowel. Radiotherapy and chemotherapy have little or no effect.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app